View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
April 26, 2019updated 12 Jul 2022 1:06pm

Gilead’s selonsertib fails in second Phase III trial for NASH

Gilead Sciences has reported that selonsertib failed to meet the primary endpoint in the Phase III STELLAR-3 clinical trial performed in patients with bridging fibrosis (F3) caused by nonalcoholic steatohepatitis (NASH).

Gilead Sciences has reported that selonsertib failed to meet the primary endpoint in the Phase III STELLAR-3 clinical trial performed in patients with bridging fibrosis (F3) caused by nonalcoholic steatohepatitis (NASH).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The announcement comes two months after the apoptosis signal-regulating kinase 1 (ASK1) inhibitor failed to demonstrate positive outcomes in the Phase III STELLAR-4 study.

In the STELLAR-3 trial, the drug did not meet the primary endpoint of a ≥1-stage histologic improvement in fibrosis without worsening NASH at week 48.

The trial investigated the safety and efficacy of selonsertib in a total of 802 patients. 9.3% of patients on 18mg selonsertib and 12.1% on 6mg dose achieved the primary endpoint.

“We believe that effective therapy for NASH will ultimately require a combination approach that targets distinct pathways.”

However, the figure was observed to be 13.2% in the placebo arm. The data also showed that selonsertib was generally well tolerated and its safety profile was consistent with previous trials.

Gilead Sciences chief scientific officer and Research and Development head John McHutchison said: “We believe that effective therapy for NASH will ultimately require a combination approach that targets distinct pathways involved in the pathogenesis of this disease.

“In this regard, we look forward to data from the Phase II ATLAS combination trial of selonsertib, cilofexor and firsocostat in patients with advanced fibrosis due to NASH, which will be available later this year.”

The randomised, double-blind, placebo-controlled STELLAR-3 trial also involved another primary endpoint of event-free survival as measured by time to the first clinical event at week 240.

Secondary endpoints of the study included proportion of patients with a ≥1-stage improvement in fibrosis without worsening NASH at week 240 and those with NASH resolution without worsening fibrosis at week 48 and week 240.

The company is set to work with the Data Monitoring Committee and investigators to appropriately conclude the STELLAR-3 trial.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena